Skip to Main Content

WASHINGTON — Sen. Ron Wyden (D-Ore.), the influential chair of the Senate Finance Committee, is promising that his signature drug pricing package won’t eviscerate small biotech companies.

Wyden, typically a fierce critic of the drug industry, is suddenly giving a shoutout to small biotech companies and their role in developing “groundbreaking new treatments.”  He’s even promising that the package he is crafting “can be tailored to the scale of these companies, as well as other factors that affect their access to capital.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment